March 11 (Reuters) - Hikma Pharmaceuticals Plc reported a 21 percent rise in full-year pretax profit, helped bystrong demand for its high-margin injectible drugs, particularlyin the United States.
The Jordanian company, which makes and markets branded andnon-branded generics and injectible drugs, also said it expected2015 revenue growth of about 6 percent in constant currencyterms.
Pretax profit rose to $362 million in the year ended Dec.31, from $298 million a year earlier.
Revenue rose 9 percent to $1.49 billion. (Reporting by Roshni Menon in Bengaluru; Editing by GopakumarWarrier)
Hikma Pharmaceuticals (HIK)
